PI3K Pathway Hyperglycemia

OncoPharm by OncoPharmPod

Sep 24, 202600:10:07Science & Medicine

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia. The mechanism of this ADR as well as the implications of which anti-diabetes medications are used in response is d...

Related Episodes

Continue listening to more episodes from OncoPharm.

Lirafugratinib + LITESPARK011

Oct 1, 2026 - 00:15:34

This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA ap...

Neutropenic Diets & Lung Cancer Updates

Sep 17, 2026 - 00:14:18

This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients o...

How to Read a Press Release and Drug Shortage Help

Sep 10, 2026 - 00:14:49

Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians le...

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates

Aug 27, 2026 - 00:20:26

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and comm...

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...

Kidney Cancer in a Nutshell

Aug 13, 2026 - 00:16:12

Overview of renal cell carcinoma Learning Oncology Companion:

Small Cell Lung Cancer and CINV Updates

Aug 6, 2026 - 00:17:35

This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (...